Grifols to evaluate potential IPO of U.S. Biopharma business

According to a regulatory filing, Grifols (GRFS) reported that, as a consequence of Grifols’ self-sufficiency programs for its Biopharma businesses, its Board of Directors has decided to initiate a process to evaluate a potential Initial Public Offering in the United States of a portion of the shares of its subsidiary and parent of its U.S. Biopharma business. Any such transaction remains subject to, among other things, regulatory and legal requirements, internal approvals and market conditions. There can be no assurance that any IPO will be undertaken or completed by the company. Regardless of any such IPO being undertaken or completed, Grifols will continue to trade in Spain through the automated information system.